CRISPR Therapeutics Is Learning How To Rewrite Disease – And Its Own Story
TL;DR
Quick Summary
- CRISPR Therapeutics (CRSP) has shifted from pure story stock to commercial-stage biotech with CASGEVY approved for sickle cell disease and beta thalassemia.
- The near-term focus (2025–2026) is whether CASGEVY can scale from a few centers into a meaningful, recurring revenue stream.
- Longer term, the upside depends on in vivo editing, off-the-shelf cell therapies, and diabetes/cardiovascular programs proving this is a true multi-product gene-editing platform.
You've reached your free daily article limit (1/1).
Create a free account to get unlimited access to all articles, market insights, and more.
Register for FreeAlready have an account? Sign in
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
Disclaimer: KAHROS is a financial media and technology company. The Services, including any AI-generated content and articles, are for informational purposes only and do not constitute financial, legal, tax, or investment advice, nor an offer or solicitation to buy or sell any securities. Market information may be time-sensitive, incomplete, or subject to change without notice. We are not a registered broker-dealer or investment advisor. Please refer to our Terms of Service for more details.
